

## EXTENDED REPORT

# Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD

Isabelle Koné-Paut,<sup>1</sup> Fhrad Shahram,<sup>2</sup> Martha Darce-Bello,<sup>1</sup> Luca Cantarini,<sup>3</sup> Rolando Cimaz,<sup>4</sup> Marco Gattorno,<sup>5</sup> Jordi Anton,<sup>6</sup> Michael Hofer,<sup>7</sup> Bouchra Chkirate,<sup>8</sup> Kenza Bouayed,<sup>9</sup> Ilknur Tugal-Tutkun,<sup>10</sup> Jasmin Kuemmerle-Deschner,<sup>11</sup> Hélène Agostini,<sup>12</sup> Sylvia Federici,<sup>5</sup> Armelle Arnoux,<sup>12</sup> Celine Piedvache,<sup>12</sup> Seza Ozen,<sup>13</sup> the PEDBD group

**Handling editor** Tore K Kvien

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2015-208491>).

For numbered affiliations see end of article.

## Correspondence to

Professor Isabelle Koné-Paut, Department of Paediatric Rheumatology and Reference Center for Autoinflammatory Diseases, Bicêtre Hospital, APHP, University of Paris SUD, 78 rue du general leclerc, Le Kremlin Bicêtre 94270, France; [isabelle.kone-paut@aphp.fr](mailto:isabelle.kone-paut@aphp.fr)

Received 1 September 2015  
Revised 23 October 2015  
Accepted 24 November 2015  
Published Online First  
23 December 2015

## ABSTRACT

**Background** We aimed to describe the main features of Behçet's disease (BD) in children in the largest prospective cohort to date and to propose a classification.

**Methods** An international expert consensus group was formed to define a data set of minimal symptoms for the inclusion of patients. Patients were entered prospectively during 66 months. Experts classified patients on a consensus basis. The concordance of two international classifications was analysed in confirmed patients with BD. Comparisons of subgroups of patients helped define consensus criteria. BD-associated clinical manifestations were also investigated in three control diseases extracted from an independent data set (Eurofever).

**Findings** In total, 42 centres from 12 countries included 230 patients; data for 219 (M/F ratio=1) could be analysed. The experts classified 156 patients (71.2%) as having confirmed BD. Males more often than females showed cutaneous, ocular and vascular symptoms and females more often genital aphthosis. Age at disease onset and skin and vascular involvement were lower for European than non-European children. Oral aphthosis was the presenting sign for 81% (179/219) of patients. The mean delay to the second symptom was 2.9 ±2.2 years. International classifications were not concordant with the expert classification. Our paediatric classification contains six categories, a minimum of three signs (each in a distinct category) defining paediatric BD. Three clinical signs discriminated our cohort from the Eurofever cohorts.

**Interpretation** We present a comprehensive description of a large cohort of patients from both European and non-European countries and propose the first classification of paediatric BD for future therapeutic trials.

## INTRODUCTION

Behçet's disease (BD) is a systemic inflammatory condition sharing the clinical features of both auto-inflammatory disease and vasculitis.<sup>1 2</sup> Its pathogenesis is still unclear, but the combination of genetic factors affecting the immune regulation and undetermined environmental triggers may explain the variability disease expression.<sup>3</sup> The clinical spectrum of BD comprises a number of organ

involvements; the pattern of skin lesions and the peculiar occurrence of thrombosis in all types of vessels represent important clues. In fact, the disease is now classified as a 'variable vessel vasculitis', which highlights the involvement of any artery and vein.<sup>4</sup> Oral aphthosis is present in almost all patients with BD (98%).<sup>5</sup> As well, BD manifestations are recurrent. Some heal without scar or sequelae, but others cause substantial morbidity, such as ophthalmological manifestations, which may cause blindness and vascular and cardiac involvements, the main causes of mortality.<sup>6</sup>

Although generally recognised in adulthood, the first BD symptoms may start early in life, and the disease is rarely completed before the age of 16 years in 4–26% of cases.<sup>7</sup> At this age, the frequency of uveitis is lower than in adults and the rate of familial aggregation is high, which strongly suggests a genetic component.<sup>8–11</sup>

BD is diagnosed when a patient presents a combination of symptoms among the most frequently observed and/or the most typical of the disease. Several international groups have attempted to propose clinical criteria for classification or diagnostic criteria in adult patients with BD. The most currently used are those developed by an international study in 1990 (see online supplementary table S1).<sup>12</sup> The sensitivity of the criteria appeared relatively low because they were not established in accordance with the geographical variations of BD phenotype. Revised criteria were proposed from a multinational collaboration of 27 countries: in addition to mucocutaneous and ocular features, the criteria included neurological and vascular involvement.<sup>13</sup> However, we lack a suitable, validated definition of BD in children, and the diagnosis remains challenging. The diagnostic criteria of paediatric BD must be sensitive as well as specific because several other conditions, especially auto-inflammatory diseases, inflammatory bowel diseases and immunodeficiency, can mimic BD.

The Paediatric Behçet's Disease (PEDBD) study was established to identify the clinical course of children presenting few symptoms of BD and for whom other diagnoses were ruled out. We wanted also to provide a paediatric BD classification to help in performing future therapeutic trials.



CrossMark

**To cite:** Koné-Paut I, Shahram F, Darce-Bello M, et al. *Ann Rheum Dis* 2016;**75**:958–964.

## AIMS OF THE PEDBD STUDY

The primary objective was to establish a prospective cohort of paediatric patients presenting a minimal set of BD signs. The secondary objectives were as follows:

- ▶ to identify a subgroup of patients with confirmed paediatric BD by an adjudication process involving expert consensus;
- ▶ to define the natural history of BD by type of symptoms and their chronology of appearance;
- ▶ to test the concordance of two international BD classification criteria with the developed expert classification, then define a paediatric classification;
- ▶ to perform an external validation of the new paediatric classification by using data from patients with other autoinflammatory diseases as negative controls.

## PATIENTS AND METHODS

### Study design

**First step: establishing an expert consensus group and minimal set of symptoms**

The expert committee of four adult specialists and three paediatricians defined the minimal set of symptoms as follows: recurrent oral aphthosis, at least three times a year, associated with at least one of the following: genital ulceration or aphthosis, vessel thrombosis or aneurysm, erythema nodosum, acneiform lesions, papulopustular lesions, skin ulceration or aphthosis, positive pathergy test, uveitis (post or panuveitis), retinal vasculitis and family history of BD (if documented).

### Inclusion/exclusion criteria for the PEDBD cohort

Patients needed to fulfil the criteria established by the expert committee and to sign an informed consent for participation according to the regulations of participating countries. They had to present a first symptom before age 16 and have no concomitant diseases interfering with BD evaluation. These were new or already known patients (maximum 3 years) and could be followed prospectively for at least 4 years. Exclusion criteria were patients who did not meet at least one of these criteria.

### Second step: establishing an electronic database, international collaboration and data entry

An online database was designed following the national regulations in France and in accordance with local regulations in each participating countries. Inclusion and update visits were recorded into a standardised format. Our clinical research unit (HA, AA, CP) provided data management. The Paediatric Rheumatology European Society, Paediatric Rheumatology International Trials Organisation and International BD society members entered their patients anonymously.

### Third step: annual review and case adjudication

The expert committee performed an annual chart review. In a round-robin format, the members collected votes to classify patients as having confirmed, probable and uncertain or no BD. Consensus was obtained with 80% agreement. Charts for patients were reviewed more than once, if necessary, until the PEDBD group closed the study, during the last meeting on 6 February 2014. Patients without diagnostic consensus at this deadline were not classified.

### Fourth step: statistical analysis

The comparison of confirmed and unconfirmed patients with BD provided a preliminary classification, which was secondarily endorsed by consensus. Patients from the Eurofever registry were

negative controls (see online supplementary information 1).<sup>4</sup> Variables included in the PEDBD score were anonymously extracted and analysed. Criteria defining BD were based on symptoms appearing before the expert classification, and the analysis of natural history was based on symptoms collected during the whole study. For univariate analyses, continuous variables are summarised with mean (SD) and categorical variables as number (percentage). Missing data were described by calculating the percentage of the total effective data and were excluded from further analyses. For bivariate analyses, the primary outcome was the expert classification (confirmed and unconfirmed BD). Symptoms, determinants of symptoms and potential associated factors were compared. The association of qualitative variables and the primary outcome (confirmed BD) was analysed by Pearson's  $\chi^2$  or Fisher's exact test and that of quantitative variables and the primary outcome was by Student's t or Mann-Whitney U test. For multivariate analysis, a logistic regression model with stepwise selection was used to investigate the association of symptoms and confirmed BD, reporting ORs and 95% CIs. Significance at  $p \leq 0.20$  was required to be included and remain in the model. Potential interactions between variables were tested. A sensitivity analysis was performed to analyse whether headache should be included in neurological symptoms. For each subject, the number of criteria was calculated from symptoms retained in the model plus oral aphthosis. The optimal number of criteria distinguishing confirmed and unconfirmed BD was established by receiver operating characteristic (ROC) curve analysis. To assess sensitivity and specificity, the agreement between the BD classification and alternative classifications was analysed by the Kappa method.<sup>12 13</sup> Symptom patterns and pathology type were explored by multiple correspondence analyses. Statistical analyses involved use of SAS V9.3 (SAS Institute, Cary, North Carolina, USA).

## RESULTS

The total duration of the PEDBD study from the first to the last inclusion was 66 months.

### Fulfilment of inclusion and non-inclusion criteria, and minor protocol deviations

In total, 227 patients were eligible and agreed to be included in the study; 53 (23.3%) were  $\geq 16$  years old at the inclusion visit. Overall, 220 had at least one symptom in addition to recurrent oral aphthosis; 7/227 (3.1%) had oral aphthosis associated with a family history of BD, and 8/227 (3.5%) who presented or showed another disease during the PEDBD study were excluded. Finally, data for 219 patients could be analysed during 717 follow-up visits (mean 3.2 visits per patient) (see online supplementary figure S1).

### Epidemiological data and whole cohort

The 219 patients (109 males) originated from 42 centres in 12 countries (not shown). The ethnic distribution was approximately one-third European Caucasian, one-third Middle Eastern Caucasian and one-third North African (not shown). The mean age at first symptom was  $7.4 \pm 4.2$  years (median 7 years, range 0–15.9 years). In addition to recurrent oral aphthosis, patients had genital aphthosis 104/219 (47.5%), necrotic folliculitis, pustular or acneiform lesions 60/198 (30.3%), erythema nodosum 37/198 (18.7%), pathergy 42/94 (44.7%), anterior uveitis 52/219 (23.7%), posterior uveitis 47/219 (21.5%), retinal vasculitis 20/219 (9.1%), papilledema 17/219 (7.8%), anterior uveitis in association with at least another posterior finding 29/52

## Criteria

**Table 1** Epidemiological characteristics of the 219 Paediatric Behçet's Disease (PEDBD) patients with confirmed and unconfirmed Behçet's disease (BD)

Characteristics	Confirmed BD n=156	Unconfirmed BD n=63	p Value
Gender, males/females, no. (%)	78 (50)/79 (50)	31 (49.2)/32 (50.8)	0.9153
Consanguinity, no. (%)*	6 (3.9)	4 (6.4)	0.4802
Familial case, no. (%)	32 (24.4)	16 (29.1)	0.5071
Age at first symptom, years	7.83±4.39	6.19±3.64	0.0105
Age at first suspicion by the physician	11.33±3.84	10.04±3.59	0.0123
Age at diagnosis, year†	13.87±3.82	–	–
Age at last visit, years	14.89±4.01	13.14±3.78	0.0020
Time from first symptom to first visit	4.54±3.35	4.85±3.88	0.8367
Disease duration, year‡	7.11±3.58	6.94±4.28	0.6485

Data are mean±SD unless indicated.

\*Unknown for five patients.

†BD diagnosis/confirmation: age at which the patient could be classified as having definite BD by the consensus of experts.

‡Disease duration: mean time between the first symptoms of BD to the last follow-up visit in the PEDBD cohort.

(18.6%), venous thrombosis 21/219 (9.6%), and arterial thrombosis or aneurysm 4/219 (1.8%).

### Classification of PEDBD patients and comparison of confirmed and unconfirmed BD

The expert committee classified 156/219 patients (71.23%) as having confirmed BD and 63 as having unconfirmed BD (probable 26, uncertain 14, no consensus 18, not BD 5). Patients with confirmed and unconfirmed BD were comparable in sex ratio (M/F=1), family history of BD, consanguinity and disease duration since the first symptom to the first and last visit (table 1). However, age at first symptom, at first suspicion and at BD confirmation was higher for confirmed than unconfirmed


patients. BD confirmation was associated with clinical symptoms of genital aphthosis ( $p=0.0004$ ) and any of the following: cutaneous (pathergy test excluded from the analysis;  $p=0.0084$ ), neurological ( $p=0.0022$ ), ocular ( $p=0.0002$ ) and vascular symptoms ( $p=0.0052$ ) (see online supplementary table S2). It was associated with the cutaneous symptoms necrotic folliculitis/acneiform lesions/folliculitis ( $p=0.0169$ ) and erythema nodosum ( $p=0.0279$ ), as well as anterior and posterior uveitis ( $p=0.0150$  and  $0.0029$ ), retinal vasculitis ( $p=0.0010$ ) and papilledema ( $p=0.0022$ ) but not presence of human leucocyte antigen B51 ( $p=0.2965$ ) (not shown).

### Descriptive data for the 156 patients with confirmed BD


Of the 156 patients with confirmed BD, half were males ( $n=78$ ) (table 1); about half (56.41%,  $n=88$ ) lived in Europe (not shown). Among them, 86 (53.8%) were <16 years at BD confirmation. The main categories of clinical symptoms at BD confirmation are given in online supplementary table S2. More detailed clinical information is available in the online supplementary file additional information no 3.

### Gender differences

The mean number of attacks per year of oral aphthosis was similar for females and males with confirmed BD ( $11.32±10.87$  and  $13.16±14.23$ ), as was the mean number of attacks of genital ulceration ( $3.42±4.46$  and  $3.85±4.40$ ) (not shown). However, the sexes differed in distribution of clinical symptoms (figure 1). Indeed, genital ulceration was associated more with females than males ( $p=0.0006$ ), and ocular symptoms as a whole and vascular symptoms were associated more with males ( $p=0.0039$  and  $0.0199$ ). Considered individually, none of the cutaneous symptoms differed between the sexes. Among the ocular symptoms, males more than females showed posterior uveitis ( $p=0.0004$ ), retinal vasculitis ( $p=0.0265$ ) and papilledema ( $p=0.0348$ ), as well as involvement of both eyes ( $p=0.0193$ ), visual acuity <1/10 ( $p=0.5766$ ) and venous thrombosis ( $p=0.0265$ ). Cranial



**Figure 1** Frequency of symptoms in 156 patients with confirmed Behçet's disease according to the gender.



**Figure 2** Chronology of symptoms in 156 patients with confirmed Behçet's disease.

nerve palsy was more common, although not significantly, in females than males ( $p=0.1165$ ).

### Regional differences

The age at first BD symptom was significantly lower for patients in European than non-European countries ( $6.84 \pm 4.66$  vs  $9.12 \pm 3.67$ ;  $p=0.0017$ ). European patients frequently showed articular ( $p=0.0527$ ) (especially axial joints;  $p=0.0061$  vs peripheral;  $p=0.0892$ ), gastrointestinal ( $p<0.0001$ ) and neurological symptoms (including headaches:  $p<0.0001$ ; without headaches but with papilledema:  $p=0.05$ ), and fever ( $p<0.0001$ ). Conversely, some symptoms more frequent for non-European patients included necrotic folliculitis, pseudo folliculitis and acneiform lesions (each  $p<0.05$ ). European and non-European patients did not differ in individual ocular symptoms, but European patients more frequently showed bilateral symptoms ( $p=0.0405$ ) that resulted in visual loss (visual acuity  $<1/10$ ;  $p=0.0447$ ). Among neurological symptoms without headaches, only long-tract dysfunction was more frequent, although not significant, in European than non-European patients ( $p=0.0687$ ). Vascular symptoms were more frequent in non-European patients.

### Chronology of symptoms and pathways of entry in BD through the PEDBD cohort study

Oral aphthosis was the presenting symptom for 81% (179/219) of patients, followed by genital ulceration, skin symptoms and fever (20.5%). The chronology of symptoms in patients with and without confirmed BD is shown in [figure 2](#) and online supplementary figure 2. The ages of onset of symptoms by classification are given in [table 2](#). The mean ages at onset of oral aphthosis ( $8.74 \pm 4.21$ ) and neurological symptoms were significantly higher for patients with confirmed than unconfirmed BD ( $p=0.0143$  and  $0.0144$ , respectively). The median delay between the first and second wave of symptoms in all patients

was 2 years (range 1–12 years; mean  $2.9 \pm 2.2$  years) (see online supplementary figure 3), and the median delay between the second and third and third and fourth waves was 1.5 years (range 1–8 years, mean  $2 \pm 1.6$ ). New symptoms occurring during follow-up were more frequent for patients with than without confirmed BD (not shown). The mean delay between the first symptom and age at BD confirmation was  $6.0 \pm 3.5$  years. One patient died of multiple thromboses.

**Table 2** Age of onset of Behçet's disease (BD) symptoms for patients with confirmed and unconfirmed BD by expert classification (Paediatric Behçet's Disease (PEDBD))

PEDBD classification	Confirmed BD n=156		Unconfirmed BD n=63		p Value
	Age	No. of patients	Age	No. of patients	
Oral aphthosis	$8.74 \pm 4.21$	156	$7.32 \pm 3.77$	63	0.0143
Genital ulceration	$11.23 \pm 4.32$	86	$10.67 \pm 3.56$	18	0.3083
Cutaneous signs	$10.36 \pm 4.30$	104	$8.85 \pm 4.51$	26	0.1072
Ocular signs	$10.94 \pm 3.62$	71	$9.18 \pm 3.22$	11	0.1192
Articular signs	$10.02 \pm 3.79$	64	$9.67 \pm 3.66$	24	0.6990
Gastrointestinal signs*	$8.87 \pm 4.60$	46	$8.17 \pm 3.75$	18	0.4539
Neurological signs*	$10.95 \pm 3.95$	93	$8.25 \pm 2.80$	51	0.0144
Vascular signs	$11.26 \pm 3.89$	23	9	1	0.6104
Fever	$8.63 \pm 4.64$	68	$8.30 \pm 4.56$	23	0.7555
Cardiac signs	$10.29 \pm 3.55$	7	15	1	0.2600
Pulmonary signs	$11.33 \pm 5.02$	9	15	1	0.4561

Data are mean  $\pm$  SD.

\*Neurological signs include patients with headaches and gastrointestinal signs include those with abdominal pain. Detailed clinical information is available in the online supplementary information file.

## Criteria

**Table 3** Consensus classification of paediatric Behçet's disease (BD)

Item	Description	Value/item
Recurrent oral aphthosis	At least three attacks/year	1
Genital ulceration or aphthosis	Typically with scar	1
Skin involvement	Necrotic folliculitis, acneiform lesions, erythema nodosum	1
Ocular involvement	Anterior uveitis, posterior uveitis, retinal vasculitis	1
Neurological signs	With the exception of isolated headaches	1
Vascular signs	Venous thrombosis, arterial thrombosis, arterial aneurysm	1

Three of six items are required to classify a patient as having paediatric BD.

### Comparison of expert classification with international criteria for BD

In all, 115/156 PEDBD patients fulfilled the ISG criteria (sensitivity 73.7%, specificity 100%;  $\kappa$  coefficient 0.62). In general, PEDBD patients discordant with the ISG criteria had only one of genital, skin and ocular symptoms. The new international PEDBD classification evaluated without the pathergy test had higher sensitivity (91.7%; 143/156 patients fulfilling both classifications) but lower specificity (42.9%,  $\kappa=0.39$ ). The addition of the pathergy test did not improve performance ( $\kappa=0.44$ ; sensitivity 96.2%, specificity 41.3%). The discordance was not improved with oral plus genital aphthosis or oral aphthosis plus ocular symptoms ( $\kappa=0.49$ ).

### Preliminary classification of paediatric BD according to the PEDBD data

Symptoms associated with BD confirmation were considered simultaneously. The categories of signs were genital ulceration and cutaneous, ocular, neurological and vascular symptoms. Several hypotheses were tested for neurological symptoms because only headaches and papilledema appeared significantly associated with confirmed BD. Two of the hypotheses are given in online supplementary table 3. All experts agreed to retain neurological symptoms as a whole; indeed, neurological symptoms were found in only confirmed patients with BD. The mean number of symptoms at the time of the expert classification was significantly higher for patients with confirmed than

unconfirmed BD ( $3.15\pm 0.89$  vs  $2.08\pm 0.6$ ;  $p<0.0001$ ) (not shown). The ROC curve for three symptoms gave sensitivity 77% and specificity 88% (not shown). Taking into account both the category of signs and number of signs significantly associated with the experts' confirmation of BD and the experts' consensus, we proposed a first classification of BD in children (table 3).

### Comparisons with the Eurofever cohort

The Eurofever registry provided data for 410 patients (220 males; mean age  $7.6\pm 3.8$  years, range 6 months to 16 years) with diseases distinct from BD, who were negative controls (ie, periodic fever adenitis pharyngitis and aphthosis (PFAPA) syndromes,  $n=259$ ; cryopyrin-associated periodic syndrome (CAPS),  $n=86$ ; and mevalonate kinase deficiency (MKD),  $n=65$ ). The mean age for our BD-confirmed patients was higher ( $p<0.0001$ ). Significant differences appeared for all categories and testing different hypotheses for ocular and neurological symptoms (table 4). For the Eurofever patients, the mean number of BD symptoms was lower for confirmed than unconfirmed patients with BD in the PEDBD population ( $p<0.0001$ ) (eg, PFAPA  $0.63\pm 0.52$ , CAPS  $0.52\pm 0.76$  and MKD  $0.8\pm 0.71$  vs  $3.15\pm 0.89$  and  $2.08\pm 0.6$ , respectively). Multiple correspondence analyses between PEDBD and Eurofever are given in online supplementary figure S4.

### DISCUSSION

BD in children is rare and challenging to recognise. We aimed to describe the main features of the disease in the largest prospective cohort to date and propose a classification of paediatric BD. Among the 219 children included (equal males and females, symptoms appearing before age 16), the experts confirmed BD in 156 (71.2%). Males more often than females had cutaneous, ocular and vascular symptoms and females more often than males had genital aphthosis. Oral aphthosis was the presenting sign in 81% of patients. International classifications were not concordant with the experts' classification. Our paediatric classification contains six categories, a minimum of three defining paediatric BD (table 3).

The main strengths of the PEDBD study are the international collaboration and its prospective study design assessing the natural history of BD. In addition, it is the first attempt to emphasise the shortcomings or limitations of the adult criteria for the paediatric population and introducing the main features in paediatric BD in the largest cohort of patients. Oral aphthosis

**Table 4** Frequency of symptoms among diseases and confirmed and unconfirmed paediatric Behçet's disease (BD)

Disease	PFAPA n=259	MKD n=65	CAPS n=86	Unconfirmed BD n=63	Confirmed BD n=156	p Value*
Age, mean $\pm$ SD	6.95 $\pm$ 3.42	8.73 $\pm$ 4.11	8.88 $\pm$ 4.24	11.91 $\pm$ 3.82	13.25 $\pm$ 3.88	<0.0001
Oral aphthosis	153	38	12	63	156	<0.0001
Genital aphthosis	0	1	0	20	91	<0.0001
Ocular sign†	1	2	6	12	67	<0.0001
Ocular signs‡	1	2	23	12	73	<0.0001
Neurologic signs	42	25	35	15	72	<0.0001
Neurologic signs¶	6	8	26	0	37	<0.0001
Vascular symptoms	0	1	0	2	27	<0.0001

Data are no. (%) unless indicated.

\*By  $\chi^2$  test.

†Ocular sign: includes at least one of anterior and posterior uveitis and retinal vasculitis.

‡Ocular signs: includes at least one of anterior and posterior uveitis, retinal vasculitis and papilledema.

¶Neurological signs: calculated without headaches and with papilledema.

CAPS, cryopyrin-associated periodic syndrome; MKD, mevalonate kinase deficiency; PFAPA, periodic fever adenitis pharyngitis and aphthosis.

was mandatory for inclusion because of its high frequency in children with BD (95%).<sup>9 11 14–17</sup> Symptoms such as vascular symptoms and family history were included because they represented a considerable share of the features of paediatric patients. To attain our first objective, to establish a prospective cohort of paediatric patients presenting a minimal set of BD signs, a remarkable effort was made during 7 years to update patient information and classify the disease each year, independent of any predefined criteria. Confirmed BD was associated with genital aphthosis, skin manifestations, neurological and vascular symptoms as well as number of attacks of oral aphthosis, visual acuity <1/10 and the presence of a median number of three symptoms. Patients with confirmed BD had an equal sex ratio and most lived outside Europe (56%). Cutaneous signs were the most frequent, and ocular symptoms and genital aphthosis were less frequently observed than in adults. Females more often than males had genital aphthosis, whereas males more often than females had ocular and vascular symptoms.<sup>7 9 18 19</sup> Age at onset and articular, gastrointestinal and neurological symptoms during follow-up were more frequent in European than non-European patients, who also had had more skin and vascular involvement, in accordance with several BD cohorts and registries.<sup>7 9 20 21</sup> Interestingly, European patients more frequently had bilateral lesions ( $p=0.0405$ ) and visual loss ( $p=0.0447$ ). A lower degree of awareness of BD uveitis in European than non-European patients could delay appropriate treatment. The second BD symptom appeared at a median of 2 years (mean  $2.9\pm 2.2$ ) and BD confirmation at  $6.0\pm 3.5$  years.<sup>8</sup> Oral ulceration was the first symptom in most cases and was generally followed by cutaneous signs, fever, articular or gastrointestinal signs. Ocular and vascular symptoms appeared later in general. The ocular involvement was associated with severe prognosis for 12.3% (27/219) of patients with visual acuity <1/10; three had permanent blindness.

To meet our final objective, we compared our 156 confirmed patients with BD with two of the international classifications designed for an adult population.<sup>12 13</sup> Both had low concordance with our expert classification. We propose a new consensus classification for paediatric BD (table 3). Six categories of symptoms were considered with their descriptions. Papilledema and headaches were the only neurological symptoms significantly associated with confirmed BD. Finally, we agreed to consider neurological symptoms as a whole but without headaches, which are not specific enough in BD.<sup>22</sup> Our PEDBD classification does not consider a positive pathergy test result and does not mention oral aphthosis as a mandatory criteria. All symptoms categories have the same weight, especially because we do not know their respective frequencies in the general paediatric population. The new paediatric BD classification could differentiate confirmed BD, with a significantly increased number of symptoms, from unconfirmed BD and PFAPA, MKD and CAPS, as negative controls.

To conclude, we have reported the widest cohort study ever performed to define paediatric BD and its natural history. The contribution of three cohorts of children from the Eurofever registry reinforces the validity of the new classification of paediatric BD, which will be a reference for further therapeutic trials, even if it still requires external validation by an independent cohort of patients with paediatric BD.

#### Author affiliations

<sup>1</sup>Department of Paediatric Rheumatology, CEREMAI, Bicêtre University Hospital, APHP, Paris SUD, Le Kremlin Bicêtre, France

<sup>2</sup>Rheumatology Research Center, Shariati Hospital, Tehran, Iran

<sup>3</sup>Department of Reumatologia, Siena, Italy

<sup>4</sup>Department of Paediatric Rheumatology, A. Meyer Children, Florence, Italy

<sup>5</sup>UO Pediatria II, G. Gaslini Scientific Institute, Genoa, Italy

<sup>6</sup>Paediatric Rheumatology Unit, Sant Joan de Déu University Hospital, Esplugues de Llobregat, Spain

<sup>7</sup>Department of Paediatric Rheumatology, Vaudois University Hospital, Lausanne, Switzerland

<sup>8</sup>Internal Medicine and Immunology Clinic, Hassan II University Hospital, Fes, Morocco

<sup>9</sup>Department of Paediatrics, IBN Rochd University Hospital, Casablanca, Morocco

<sup>10</sup>Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

<sup>11</sup>Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tübingen, Tübingen, Germany

<sup>12</sup>Clinical Research Unit, Bicêtre University Hospital, APHP, Paris SUD, Le Kremlin Bicêtre, France

<sup>13</sup>Department of Paediatrics, Hacettepe University, Ankara, Turkey

**Acknowledgements** Thanks to N Levy, K Bertaux, Marseille, France; K Sylla, A Letierce, L Coutard, Kremlin-Bicêtre, France, for the clinical research department of the AP-HP, and the Eurofever network. And to Laura Smales for reviewing English editing.

**Collaborators** PED-BD international expert committee: S Ozen, H Ozdogan, A Gul, F Shahram, M Hofer, M Gattorno, R Cimaz, I Koné-Paut. *The PEDBD group*: French collaborators: K Retornaz, AL Jurquet, I Touitou, M Barat, Montpellier; P Quartier, A Faye, Paris, V Despert, Rennes, C Pajot, Toulouse, I Lemelle, Nancy, JL Boussioux, Martigues, TA Tran, Nimes. *International collaborators*: N Mikou, S Benamour, Casablanca and W Bono, Fes, Morocco; O Kasapcopur, H Ozdogan, A Gul, Istanbul, Turkey; S Al Mayouf, Riyadh, Saudi Arabia; R Khubchandani, Mumbai, India; S Assad Khalil, Alexandria, Egypt; F Davatchi, Tehran, Iran; S Hansmann, Tübingen, Germany; S Nielsen, Copenhagen, Denmark; A Benzaoui, Oran and K Tir, Algiers, Algeria; N Ruperto, A Naseli, Genoa and L Lepore, Trieste, Italy.

**Contributors** IK-P conceived and coordinated the study. She also obtained the grant and wrote the manuscript. IK-P, FS, MD-B, LC, RC, MG, JO, MH and SO participated each year in the consensus conference to classify PEDBD patients. All authors, except HA, AA and CP, made substantial contributions to the acquisition of data. HA contributed to the study design. IK-P, MG, AA, CP, HA and SO made substantial contributions to the analysis and interpretation of data. MG and SF provided patient data for the negative control (Eurofever data) for external validation of the paediatric BD classification. MG, FS, RC, JA, SO and CP helped draft the manuscript. All authors read and approved the final manuscript.

**Funding** This study was supported by the AP-HP Programme hospitalier de recherche clinique, (PHRC2007) of the French ministry of health (no. AOR07002).

**Competing interests** IK-P has received consultancy fees from SOBI Biovitrum, Novartis, Pfizer, Abbvie, Roche Chugai and speaker fees from Pfizer and Novartis. She also received clinical research support from SOBI Biovitrum and Roche Chugai. JA has received consulting fees from Pfizer, Abbvie, SOBI, Roche and Novartis and a research grant from Roche and Novartis. MH has received consulting fees from Novartis and Abbvie and research grant from Abbvie. IT-T has received personal fees from Servier and Abbvie. JK-D and MG has received speaker fees from Novartis and SOBI. SO has received speaker fees from SOBI and consulting fees from Novartis.

**Ethics approval** IRB approval was obtained.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Additional unpublished data are available to the main investigators and statisticians in a database located at the research unit of the Bicêtre hospital.

#### REFERENCES

- Barnes CG, Yazici H. Behçet's syndrome. *Rheumatology* 1999;38:1171–6.
- Shimizu T, Ehrlich GE, Inaba G, et al. Behçet's disease. *Sem Arthritis Rheum* 1979;8:223–60.
- Sakane T, Takano M, Suzuki N, et al. Behçet's disease. *N Engl J Med* 1999;341:1284–91.
- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1–11.
- Faezi ST, Paragomi P, Shahram F, et al. Clinical features of Behçet's disease in patients without oral aphthosis. *Mod Rheumatol* 2014;24:637–9.
- Savey L, Resche-Rigon M, Wechsler B, et al. Ethnicity and association with disease manifestations and mortality in Behçet's disease. *Orphanet J Rare Dis* 2014;9:42.
- Kötter I, Vonthein R, Müller CA, et al. Behçet's disease in patients of German and Turkish origin living in Germany: a comparative analysis. *J Rheumatol* 2004;31:133–9.

## Criteria

- 8 Alpsöy E, Donmez L, Onder M, *et al*. Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study. *Br J Dermatol* 2007;157:901–6.
- 9 Koné-Paut I, Yurdakul S, Bahabri SA, *et al*. Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. *J Pediatr* 1998;132:721–5.
- 10 Koné-Paut I, Geisler I, Wechsler B, *et al*. Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. *J Pediatr* 1999;135:89–93.
- 11 Karıncaoğlu Y, Borlu M, Toker SC, *et al*. Demographic and clinical properties of juvenile-onset Behçet's disease: A controlled multicenter study. *J Am Acad Dermatol* 2008;58:579–84.
- 12 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet* 1990;335:1078–80.
- 13 International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol* 2014;28:338–47.
- 14 Toplak N, Frenkel J, Ozen S, *et al*. An international registry on autoinflammatory diseases: the Eurofever experience. *Ann Rheum Dis* 2012;71:1177–82.
- 15 Kim DK, Chang SN, Bang D, *et al*. Clinical analysis of 40 cases of childhood-onset Behçet's disease. *Pediatric Dermatol* 1994;11:95–101.
- 16 Pivetti Pezzi P, Accorinti M, Abdulaziz MA, *et al*. Behçet's disease in children. *Jpn J Ophthalmol* 1995;39:309–14.
- 17 Krause I, Uziel Y, Guedj D, *et al*. Childhood Behçet's disease: clinical features and comparison with adult-onset disease. *Rheumatology (Oxford)* 1999;38:457–62.
- 18 Bonitsis NG, Luong Nguyen LB, LaValley MP, *et al*. Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. *Rheumatology (Oxford)* 2015;54:121–33.
- 19 Tursten U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. *Int J Dermatol* 2003;42:346–51.
- 20 Mahr A, Belarbi L, Wechsler B, *et al*. Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. *Arthritis Rheum* 2008;58:3951–9.
- 21 Calamia KT, Wilson FC, Icen M, *et al*. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. *Arthritis Rheum* 2009;61:600–4.
- 22 Vishwanath V, Wong E, Crystal SC, *et al*. Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience. *Curr Pain Headache Rep* 2014;18:445.



## Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD

Isabelle Koné-Paut, Fahrads Shahram, Martha Darce-Bello, Luca Cantarini, Rolando Cimaz, Marco Gattorno, Jordi Anton, Michael Hofer, Bouchra Chkirate, Kenza Bouayed, Ilknur Tugal-Tutkun, Jasmin Kuemmerle-Deschner, H el ene Agostini, Sylvia Federici, Armelle Arnoux, Celine Piedvache and Seza Ozen

*Ann Rheum Dis* 2016 75: 958-964 originally published online December 23, 2015  
doi: 10.1136/annrheumdis-2015-208491

---

Updated information and services can be found at:  
<http://ard.bmj.com/content/75/6/958>

---

*These include:*

### Supplementary Material

Supplementary material can be found at:  
<http://ard.bmj.com/content/suppl/2015/12/23/annrheumdis-2015-208491.DC1>

### References

This article cites 22 articles, 5 of which you can access for free at:  
<http://ard.bmj.com/content/75/6/958#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Ophthalmology](#) (128)  
[Vasculitis](#) (294)  
[Epidemiology](#) (1367)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>